Accelerator mass spectrometry analysis of ¹⁴C-oxaliplatin concentrations in biological samples and ¹⁴C contents in biological samples and antineoplastic agents

详细信息    查看全文

• 作者：Teiko Toyoguchi^a ; ^{tteiko@med.id.yamagata-u.ac.jp" class="auth_mail" title="E-mail the corresponding author} ; Takeshi Kobayashi^a ; Noboru Konno^a ; Tadashi Shiraishi^a ; Kazuhiro Kato^b ; Fuyuki Tokanai^b
• 关键词：Accelerator mass spectrometry ; 14C-oxaliplatin ; Urine ; Antineoplastic agents
• 刊名：Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms
• 出版年：2015
• 出版时间：15 October 2015
• 年：2015
• 卷：361
• 期：Complete
• 页码：559-563
• 全文大小：589 K

文摘

Accelerator mass spectrometry (AMS) is expected to play an important role in microdose trials. In this study, we measured the ¹⁴C concentration in ¹⁴C-oxaliplatin-spiked serum, urine and supernatant of fecal homogenate samples in our Yamagata University (YU) – AMS system. The calibration curves of ¹⁴C concentration in serum, urine and supernatant of fecal homogenate were linear (the correlation coefficients were ⩾0.9893), and the precision and accuracy was within the acceptance criteria.

To examine a ¹⁴C content of water in three vacuum blood collection tubes and a syringe were measured. ¹⁴C was not detected from water in these devices. The mean ¹⁴C content in urine samples of 6 healthy Japanese volunteers was 0.144 dpm/mL, and the intra-day fluctuation of ¹⁴C content in urine from a volunteer was little. The antineoplastic agents are administered to the patients in combination. Then, ¹⁴C contents of the antineoplastic agents were quantitated. ¹⁴C contents were different among 10 antineoplastic agents; ¹⁴C contents of paclitaxel injection and docetaxel hydrate injection were higher than those of the other injections.

These results indicate that our quantitation method using YU-AMS system is suited for microdosing studies and that measurement of baseline and co-administered drugs might be necessary for the studies in low concentrations.